DALLAS, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Gradalis, Inc., a clinical-stage biotechnology company developing personalized anti-cancer therapies, announced GRAD1405 has demonstrated robust, dose-related tumor growth control. GRAD1405 is a single agent that has demonstrated the ability to consistently reduce three KRAS mutant proteins: KRAS G12C, G12D and G12V, which are responsible for the rapid resistance to existing therapies and a resulting loss of efficacy. This approach may eliminate the need for multiple therapeutic compounds to address the different genes. Additionally, a precursor of GRAD1405 tested in a pancreatic cancer animal model showed improved benefit, suppression of tumor growth beyond 30 days and no evidence of resistance, over existing therapies. GRAD1405 achieves the silencing of specific genes using Gradalis’ proprietary bi-shRNAi technology, which has consistently reduced targeted genes in clinical trials in multiple cancer indications.

See the rest here:
Gradalis’ GRAD1405 bi-shRNAi Candidate First to Show Positive Impact on Three Key KRAS Mutations Identified in Drug Resistant Lung, Colon and...